ESPEROVAX SIGNS EXCLUSIVE LICENSING AGREEMENT WITH THE UNIVERSITY OF MICHIGAN FOR A NOVEL MANUFACTURING TECHNOLOGY FOR THE PRODUCTION OF VACCINES AND THERAPEUTICS
ANN ARBOR, Mich., Nov. 30, 2022 /PRNewswire/ -- Esperovax, a leading developer of oral vaccines, today announced it has signed a new, exclusive licensing agreement with Innovation Partners at the University of Michigan to produce vaccines and therapeutics using a novel yeast-based manufacturing method. This next-generation manufacturing technology will accelerate current programs to the clinic by allowing for a continuous purification process. In turn, such vaccines can be purified and produced with higher yields at optimal cost.